RxDoctor Payments DataLook up a doctor →

Gates Colbert, MD

Nephrology · Dallas, TXNPI 1992017545

Payments from drug & device makers

$827,651in general payments, 2019–2025

Across 2,167 payments — averaging $381.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$255K
  • AstraZeneca$163K
  • GSK$121K
  • Daiichi Sankyo Inc.$99K
  • Bayer$66K
  • Johnson & Johnson$34K
  • plus $89K from 43 others

What the payments were for

  • Consulting fees$83,13210%
  • Speaking & faculty fees$607,42673%
  • Travel & lodging$91,67111%
  • Food & beverage$44,8495%
  • Education$5740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827,651 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$314,745
Medicare patients
476
Services billed
2,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol105$84,343
RayaldeeCalcifediol65$78,509
VelphoroSucroferric Oxyhydroxide14$43,824
KerendiaFinerenone39$37,875
JardianceEmpagliflozin34$23,761
VeltassaPatiromer Calcium Sorbitex20$16,773
Cinacalcet Hcl15$7,600
AuryxiaFerric Citrate11$7,369
Sevelamer Carbonate18$4,837
Chlorthalidone106$1,691
Nifedipine ErNifedipine51$1,585
Spironolactone117$1,568
Losartan Potassium115$1,259
Furosemide168$807
Amlodipine Besylate105$799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$163,112$84,343105 claims
OPKO Pharmaceuticals, LLCRayaldee$1,263$78,50965 claims
Fresenius USA Marketing, Inc.Velphoro$786$43,82414 claims
BayerKerendia$66,162$37,87539 claims
Boehringer IngelheimJardiance$9,791$23,76134 claims
Akebia Therapeutics IncAuryxia$24,331$7,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →